545 results on '"de Castro, J."'
Search Results
2. Variation of quality of life in patients with obstructive sleep apnea hipopnea syndrome after treatment with mandibular advance device
3. Effects of Resistance Training with Blood Flow Restriction on Muscle Strength and Biomarkers in Older People: A Systematic Review of Randomized Clinical Trials
4. P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC
5. P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study
6. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy
7. Risk of detecting prostate cancer based on the PSAD and PIRADS lesions in MRI in patients with a negative previous biopsy.
8. Quality of life in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) subjected to intravesical instillations with BCG induction
9. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
10. In Vivo Evaluation of the Biocompatibility of Biomaterial Device
11. Mer for cognition: an emotion analysis algorithm in identifying moods of song and valence through musical features
12. Behavior of Electrical Reactance in Gastrocnemius Muscle of Rats During Contractions of Different Intensities
13. Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy
14. Behavior of Electrical Resistance in Gastrocnemius Muscle of Rats During Contractions with Different Intensities
15. PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)
16. Evaluation of Endo 10 mobile application as diagnostic tool in endodontics
17. EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression
18. Prostate rebiopsy in patients with a negative previous biopsy and MRI. When should it be done?
19. Revision of TD1 and TD2 stratigraphic sequence of Gran Dolina cave (Sierra de Atapuerca, Spain)
20. Basal characteristics of the prospective spanish immunotherapy registry of cardiovascular toxicity: SIR-CVT
21. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
22. EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
23. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
24. 989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
25. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
26. EP08.01-049 Unscheduled Hospitalizations in Patients With Thoracic Tumors in the Era of Immunotherapy
27. Nefrectomía parcial y radical laparoscópica en tumores renales cT1. Análisis comparativo de complicaciones y supervivencia
28. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
29. Laparoscopic nephron sparing surgery and radical nephrectomy in cT1 renal tumors. Comparative analysis of complications and survival
30. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
31. Study of the immunologic response of marine-derived collagen and gelatin extracts for tissue engineering applications
32. Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
33. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
34. Development of a predictive model for optimizing the selection of patients for second transurethral resection bladder (TURB)
35. Renal tumors with left renal vein tumoral thrombosis. Is Preoperative Renal Artery Embolization (PRAE) helpful?
36. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy
37. MA14.02 RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
38. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study
39. Biomimetic and cell-based nanocarriers – New strategies for brain tumor targeting
40. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
41. Which ultrasound or MRI characteristics demonstrate the highest diagnostic accuracy in identifying malignancy in males with indeterminate lesions of the testis? A systematic review
42. Comparación entre prostatectomía laparoscópica y abierta: análisis de la evolución oncológica
43. Comparison between laparoscopic and open prostatectomy: Oncological progression analysis
44. Genomic profiling in non-small-cell lung cancer in young patients. A systematic review
45. Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence
46. Análisis de supervivencia de los pacientes con cáncer de próstata con factores patológicos desfavorables tratados con prostatectomía radical y radioterapia de rescate tras la recidiva y persistencia bioquímica
47. PCN90 Economic IMPACT of the NSCLC Molecular Diagnosis in Spain: A Retrospective Analysis of Healthcare Resources Use and Associated Costs from the LUNG-One Study
48. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy
49. Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
50. External iliac artery dissection with prosthesis replacement in renal transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.